Previous close | 2.6600 |
Open | 2.6600 |
Bid | 2.2500 |
Ask | 3.9000 |
Strike | 4.00 |
Expiry date | 2024-06-21 |
Day's range | 2.6600 - 2.6600 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Data from a late-stage study shows that treatment with J&J's (JNJ) experimental drug met all study endpoints in depression patients with insomnia symptoms.
Data from an earlier cut-off date shows that treatment with Merus' (MRUS) combination therapy achieved a 60% response rate in patients with head and neck cancer.
Iovance (IOVA) shares updated data from a mid-stage study, which showed that treatment with its combination therapy achieved an objective response rate of 65% in frontline advanced melanoma.